Bellicum closes $34.4M Series B, eyes CAR T cells for ‘safety switch’
By Marie Powers
Tuesday, January 7, 2014
Privately held Bellicum Pharmaceuticals Inc. added another $14.7 million from existing investors, including AVG Ventures and Remeditex Ventures, to its fully subscribed Series B, ratcheting the total raise from the round to $34.4 million and extending the company’s runway into 2015.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.